How I treat childhood CML

Area of Science:

• Hematology
• Pediatric Oncology
• Pharmacology

Background:

• Chronic myeloid leukemia (CML) is rare in children, complicating evidence-based treatment guidelines.
• Imatinib and subsequent tyrosine kinase inhibitors (TKIs) have transformed adult CML care, reducing the need for stem cell transplantation.
• Pediatric stem cell transplantation is generally well-tolerated, creating treatment controversies.

Observation:

• A case of a 12-month-old with BCR-ABL(+) CML highlights treatment decision challenges.
• Review of pediatric stem cell transplantation outcomes and TKI experience.
• Comparison of side effects and costs between TKI therapy and allogeneic stem cell transplantation.

Findings:

• Frontline TKI therapy is recommended for pediatric CML in chronic phase, without preceding transplantation.
• Stem cell transplantation should be considered for accelerated or blast crisis phases, or TKI resistance/intolerance.
• Adult data can guide pediatric CML treatment, but infant-specific issues require further study.

Implications:

• TKIs offer a preferred frontline approach for pediatric CML, aligning with adult treatment paradigms.
• Further research is needed on infant CML, drug formulations, pharmacokinetics, and adolescent adherence to TKIs.
• This approach aims to optimize outcomes while minimizing risks associated with transplantation in pediatric CML.